ArticleScience China. Life sciences2026
circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circular RNAs in Plasma and Beyond: Potential Biomarkers for Breast Cancer.Oncology research · 2026Review
- [The mitochondrial protein encoded by circUSP25 promotes colon cancer cell proliferation and migration].Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) often acquires resistance to platinum-based chemotherapy, presenting significant challenges to therapeutic management and adversely affecting patient survival. In such refractory cases, even advanced treatment modalities often exhibit diminished efficacy. This study aims to elucidate the molecular mechanisms underlying platinum resistance. Circular RNA circSCAP was found to be markedly upregulated in platinum-resistant TNBC and shown to encode a peptide, SCAP-129aa, which is likewise elevated in resistant tumors. Functional analyses revealed that silencing circSCAP in resistant tumors restores sensitivity to platinum-based chemotherapy, whereas its overexpression in sensitive tumors induces resistance. Mechanistically, SCAP-129aa directly interacts with the SH2C domain of PIK3R2, inhibiting its ubiquitination and subsequent degradation. This interaction stabilizes PIK3R2 protein and activates the PI3K/AKT signaling pathway, a key mediator of chemoresistance. Notably, in vivo studies further indicated that either silencing circSCAP or co-administering the PIK3R2 inhibitor SAR-260301 with platinum significantly improves treatment efficacy in resistant TNBC models. These findings establish circSCAP and SCAP-129aa as promising biomarkers and potential therapeutic targets for overcoming platinum resistance in TNBC.
Indexed as
Identifiers
40892182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.